Reich K, et al. - For moderate-to-severe psoriasis for up to 148 weeks, researchers assessed the long-term effectiveness and safety of tildrakizumab [a specific anti-IL-23p19 monoclonal antibody approved for plaque psoriasis treatment] treatment. Effectiveness was evaluated for responders (PASI75) and partial responders (PASI≥50 to <75) to tildrakizumab 100 and 200 mg at week 28 who were maintained on the same dose (administered every 12 weeks), and for partial responders or non-responders (PASI<50) to etanercept 50 mg at week 28 who were switched to tildrakizumab 200 mg after a 4-week washout (administered at weeks 32, 36, and every 12 weeks thereafter). According to this pooled analyses of two randomised phase III clinical trials (reSURFACE 1 and reSURFACE 2), tildrakizumab was well-tolerated and effectiveness was well-maintained in week 28 responders who continued treatment with tildrakizumab for 3 years or improved among etanercept partial responders/non-responders who switched to tildrakizumab.